{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:13:55Z","timestamp":1760058835550,"version":"build-2065373602"},"reference-count":64,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Breast cancer, the most prevalent cancer among women globally, develops primarily in the breast\u2019s ducts or lobules. Drug resistance is a significant challenge in treating advanced cases, contributing to over 685,000 breast cancer-related deaths annually, and identifying novel compounds that inhibit key proteins is crucial for developing effective therapies. Methods: In this study, five transferase proteins with PDB IDs were selected due to their involvement in breast cancer: 1A52, 3PP0, 4EJN, 4I23, and 7R9V. Multitargeted docking studies were conducted using three different docking strategies and Molecular Mechanics\/Generalized Born Surface Area (MM\/GBSA) to calculate the binding affinities against the ZINC Natural compound library. Isoetin (ZINC000006523948), found mainly in Isoetaceae, was identified, and the results were compared with the Food and Drug Administration (FDA)-approved drug Tucatinib. In addition, molecular interaction fingerprints and pharmacokinetic profiling were evaluated. We also performed 5 ns WaterMap simulations to identify hydration sites and interactions, followed by 100 ns molecular dynamics (MD) simulations and MM\/GBSA to assess the stability of the Isoetin\u2013protein complexes. Results: The docking results indicated that Isoetin demonstrated superior binding and docking scores ranging from \u22129.901 to \u221213.903 kcal\/mol compared to Tucatinib, which showed values between \u22124.875 and \u221210.948 kcal\/mol, suggesting Isoetin\u2019s potential efficacy as a therapeutic agent for breast cancer. Interaction fingerprints revealed significant interactions between Isoetin and key residues, including 28LEU, 12MET, 9PHE, 7ASP, 6ASN, and 6THR. The pharmacokinetics and DFT analysis of Isoetin supported its potential as a viable drug candidate. Furthermore, the 5 ns WaterMap simulations identified various hydration sites, and the 100 ns MD simulations showed that the Isoetin\u2013protein complexes exhibited minimal deviations and fluctuations, indicating better stability than Tucatinib, and MM\/GBSA confirmed Isoetin\u2019s superior binding stability. Conclusions: Isoetin, a natural compound identified through in silico screening, demonstrates significant promise as a potential therapeutic agent for breast cancer as it outperforms the FDA-approved drug Tucatinib, the respective native and FDA-approved drug. However, experimental validation is necessary before considering Isoetin for clinical use.<\/jats:p>","DOI":"10.3390\/ph18050662","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:35:13Z","timestamp":1746185713000},"page":"662","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Isoetin from Isoetaceae Exhibits Superior Pentatransferase Inhibition in Breast Cancer: Comparative Computational Profiling with FDA-Approved Tucatinib"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0079-8646","authenticated-orcid":false,"given":"Abdulaziz H.","family":"Al Khzem","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7702-9379","authenticated-orcid":false,"given":"Mansour S.","family":"Alturki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ohood K.","family":"Almuzaini","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 24342, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0080-4799","authenticated-orcid":false,"given":"Saad M.","family":"Wali","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah 24342, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4929-7071","authenticated-orcid":false,"given":"Mohammed","family":"Almaghrabi","sequence":"additional","affiliation":[{"name":"Department of Pharmacognosy and Pharmaceutical Chemistry, Faculty of Pharmacy, Taibah University, Al Madinah Al Munawarah 30001, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1298-4863","authenticated-orcid":false,"given":"Mohammed F.","family":"Aldawsari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3808-548X","authenticated-orcid":false,"given":"Maram H.","family":"Abduljabbar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, Taif 21944, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5028-8386","authenticated-orcid":false,"given":"Reem M.","family":"Alnemari","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-7024","authenticated-orcid":false,"given":"Atiah H.","family":"Almalki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia"},{"name":"Addiction and Neuroscience Research Unit, College of Pharmacy, Taif University, Al-Hawiah, Taif 21944, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8585-0888","authenticated-orcid":false,"given":"Thankhoe A.","family":"Rants\u2019o","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA"},{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e36905","DOI":"10.1097\/MD.0000000000036905","article-title":"Breast cancer: A review of risk factors and diagnosis","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Smolarz, B., Nowak, A.Z., and Romanowicz, H. (2022). Breast cancer\u2014Epidemiology, classification, pathogenesis and treatment (review of literature). Cancers, 14.","DOI":"10.3390\/cancers14102569"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Contiero, P., Boffi, R., Borgini, A., Fabiano, S., Tittarelli, A., Mian, M., Vittadello, F., Epifani, S., Ardizzone, A., and Cirilli, C. (2023). Causes of death in women with breast cancer: A risks and rates study on a population-based cohort. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1270877"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"102668","DOI":"10.1016\/j.dnarep.2019.102668","article-title":"How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?","volume":"81","author":"Venkitaraman","year":"2019","journal-title":"DNA Repair"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s43055-020-00175-5","article-title":"A review of various modalities in breast imaging: Technical aspects and clinical outcomes","volume":"51","author":"Iranmakani","year":"2020","journal-title":"Egypt. J. Radiol. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.29010","article-title":"Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next-generation sequencing with a 25-gene panel","volume":"121","author":"Tung","year":"2015","journal-title":"Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clbc.2016.05.012","article-title":"Classification, treatment strategy, and associated drug resistance in breast cancer","volume":"16","author":"Tang","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2100300","DOI":"10.1002\/minf.202100300","article-title":"Multi-targeted drug repurposing approach for breast cancer via integrated functional network analysis","volume":"41","author":"Kandasamy","year":"2022","journal-title":"Mol. Inform."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.2147\/OTT.S152462","article-title":"Functional miRNAs in breast cancer drug resistance","volume":"11","author":"Hu","year":"2018","journal-title":"Oncotargets Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bcp.2012.01.002","article-title":"Role of breast cancer resistance protein (BCRP\/ABCG2) in cancer drug resistance","volume":"83","author":"Natarajan","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: The next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11030-023-10648-0","article-title":"Identification of 5-nitroindazole as a multitargeted inhibitor for CDK and transferase kinase in lung cancer: A multisampling algorithm-based structural study","volume":"28","author":"Ahmad","year":"2024","journal-title":"Mol. Divers."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1080\/07391102.2023.2209673","article-title":"Multisampling-based docking reveals Imidazolidinyl urea as a multitargeted inhibitor for lung cancer: An optimisation followed multi-simulation and in-vitro study","volume":"42","author":"Ahmad","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2174\/1570180818666210521111535","article-title":"A multi-target approach for the discovery of anti breast cancer agents from plants secondary metabolites","volume":"18","author":"Olawale","year":"2021","journal-title":"Lett. Drug Des. Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1073\/pnas.95.11.5998","article-title":"Crystallographic comparison of the estrogen and progesterone receptor\u2019s ligand binding domains","volume":"95","author":"Tanenbaum","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18756","DOI":"10.1074\/jbc.M110.206193","article-title":"Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein","volume":"286","author":"Aertgeerts","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1021\/jm300276x","article-title":"Discovery and optimization of a series of 3-(3-Phenyl-3 H-imidazo [4,5-b] pyridin-2-yl) pyridin-2-amines: Orally bioavailable, selective, and potent ATP-independent Akt inhibitors","volume":"55","author":"Ashwell","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.str.2012.11.014","article-title":"Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition","volume":"21","author":"Gajiwala","year":"2013","journal-title":"Structure"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1021\/jacs.1c13568","article-title":"Covalent proximity scanning of a distal cysteine to target PI3K\u03b1","volume":"144","author":"Borsari","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sahu, A., Ahmad, S., Imtiyaz, K., Kizhakkeppurath Kumaran, A., Islam, M., Raza, K., Easwaran, M., Kurukkan Kunnath, A., Rizvi, M.A., and Verma, S. (2023). In-silico and in-vitro study reveals Ziprasidone as a potential aromatase inhibitor against breast carcinoma. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-43789-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100227","DOI":"10.1016\/j.phyplu.2022.100227","article-title":"Screening of phytochemicals as potential inhibitors of breast cancer using structure based multitargeted molecular docking analysis","volume":"2","author":"Jha","year":"2022","journal-title":"Phytomed. Plus"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Aloqbi, A.A., Alahdal, H., Alqosaibi, A.I., Alnamshan, M.M., Al-Dhuayan, I.S., Al-Eidan, A.A., Alzahrani, H.A., ALaqeel, N.K., Alsharif, F.H., and Al Tuwaijri, A. (2025). Lucidin from Rubia cordifolia Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins. Pharmaceuticals, 18.","DOI":"10.3390\/ph18010068"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1535-7163.MCT-21-0847","article-title":"Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer\u2013targeted therapies","volume":"21","author":"Huang","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_25","first-page":"39","article-title":"The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer","volume":"9","author":"Sirhan","year":"2022","journal-title":"Mil. Med. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/13543784.2025.2472411","article-title":"Tucatinib in the treatment of HER2-overexpressing gastrointestinal cancers: Current insights and future prospects","volume":"34","author":"Hoyek","year":"2025","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_27","unstructured":"Zhou, F., and Ding, K. (2024). Tucatinib (Tukysa): An Oral, Selective HER2 Inhibitor for the Treatment of HER2-Positive Solid Tumors. Chemistry and Pharmacology of Drug Discovery, John Wiley & Sons, Inc."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"155607","DOI":"10.1016\/j.prp.2024.155607","article-title":"A review on tyrosine kinase inhibitors for targeted breast cancer therapy","volume":"263","author":"Sankarapandian","year":"2024","journal-title":"Pathol.-Res. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Liu, H.-N., Zhu, Y., Chi, Y., Zhang, Y., Li, X., Wen, W., Shan, L.-S., Wang, Y.-T., and Dai, B. (2024). Synthetic routes and clinical application of Small-Molecule HER2 inhibitors for cancer therapy. Bioorg. Chem., 151.","DOI":"10.1016\/j.bioorg.2024.107653"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ahmad, S., Bano, N., Khanna, K., Gupta, D., and Raza, K. (2024). Reporting multitargeted potency of Tiaprofenic acid against lung cancer: Molecular fingerprinting, MD simulation, and MTT-based cell viability assay studies. Int. J. Biol. Macromol., 276.","DOI":"10.1016\/j.ijbiomac.2024.133872"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ahmad, S., Bano, N., and Raza, K. (2025). Evaluating the polypharmacological potency of FEDPN from ChEMBL BioAssays against lung cancer EGFR, ALK, TrkA and KRAS proteins. Int. J. Biol. Macromol., 306.","DOI":"10.1016\/j.ijbiomac.2025.141703"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/1061186X.2024.2347358","article-title":"An extensive review on lung cancer therapeutics using machine learning techniques: State-of-the-art and perspectives","volume":"32","author":"Ahmad","year":"2024","journal-title":"J. Drug Target."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ahmad, S., Singh, A.P., Bano, N., Raza, K., Singh, J., Medigeshi, G.R., Pandey, R., and Gautam, H.K. (2024). Integrative analysis discovers Imidurea as dual multitargeted inhibitor of CD69, CD40, SHP2, lysozyme, GATA3, cCBL, and S-cysteinase from SARS-CoV-2 and M. tuberculosis. Int. J. Biol. Macromol., 270.","DOI":"10.1016\/j.ijbiomac.2024.132332"},{"key":"ref_34","first-page":"369","article-title":"The Incipient Role of Computational Intelligence in Oncology: Drug Designing, Discovery, and Development","volume":"Volume 1016","author":"Karwasra","year":"2022","journal-title":"Computational Intelligence in Oncology"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Tripathi, M.K., Ahmad, S., Tyagi, R., Dahiya, V., and Yadav, M.K. (2022). Fundamentals of molecular modeling in drug design. Computer Aided Drug Design (CADD): From Ligand-Based Methods to Structure-Based Approaches, Elsevier.","DOI":"10.1016\/B978-0-323-90608-1.00001-0"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s42250-023-00604-8","article-title":"Comprehensive computational studies of naturally occurring kuguacins as antidiabetic agents by targeting visfatin","volume":"6","author":"Famuyiwa","year":"2023","journal-title":"Chem. Afr."},{"key":"ref_37","unstructured":"Maestro, S. (2024). Maestro, Schr\u00f6dinger, LLC."},{"key":"ref_38","unstructured":"Release, S. (2024). LigPrep, Schr\u00f6dinger, LLC."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/ja00214a001","article-title":"The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin","volume":"110","author":"Jorgensen","year":"1988","journal-title":"J. Am. Chem. Soc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10822-007-9133-z","article-title":"Epik: A software program for pK a prediction and protonation state generation for drug-like molecules","volume":"21","author":"Shelley","year":"2007","journal-title":"J. Comput.-Aided Mol. Des."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ahmad, S., Dahiya, V., Vibhuti, A., Pandey, R.P., Tripathi, M.K., and Yadav, M.K. (2023). Therapeutic protein-based vaccines. Protein-Based Therapeutics, Springer Nature.","DOI":"10.1007\/978-981-19-8249-1_13"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Ahmad, S., Kishan, A., Chitkara, P., Asiri, S.A., Eswaran, M., Mehta, S., and Alam, M. (2023). Natural product-based drug designing for treatment of human parasitic diseases. Natural Product Based Drug Discovery Against Human Parasites: Opportunities and Challenges, Springer Nature.","DOI":"10.1007\/978-981-19-9605-4_3"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1080\/07391102.2022.2060308","article-title":"Reporting dinaciclib and theodrenaline as a multitargeted inhibitor against SARS-CoV-2: An in-silico study","volume":"41","author":"Ahmad","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.53388\/MDM202508008","article-title":"RCSB Protein Data Bank: Revolutionising drug discovery and design for over five decades","volume":"8","author":"Ahmad","year":"2025","journal-title":"Med. Data Min."},{"key":"ref_45","unstructured":"Release, S. (2024). Schr\u00f6dinger Suite 2024 Protein Preparation Wizard, Epik, Schr\u00f6dinger, LLC."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: Consistent treatment of internal and surface residues in empirical p K a predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"J. Chem. Theory Comput."},{"key":"ref_47","unstructured":"Release, S. (2024). Receptor Grid Generation, Schr\u00f6dinger, LLC."},{"key":"ref_48","unstructured":"Release, S. (2024). Glide, Schr\u00f6dinger, LLC."},{"key":"ref_49","unstructured":"QikProp, S. (2024). Schr\u00f6dinger Release 2024, Maestro LLC."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Acharya, R., Chacko, S., Bose, P., Lapenna, A., and Pattanayak, S.P. (2019). Structure based multitargeted molecular docking analysis of selected furanocoumarins against breast cancer. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-52162-0"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"135701","DOI":"10.1016\/j.molstruc.2023.135701","article-title":"Synthesis, single crystal, TD-DFT, molecular dynamics simulation and DNA binding studies of carbothioamide analog","volume":"1287","author":"Rana","year":"2023","journal-title":"J. Mol. Struct."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/qua.24481","article-title":"Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences","volume":"113","author":"Bochevarov","year":"2013","journal-title":"Int. J. Quantum Chem."},{"key":"ref_53","unstructured":"Release, S. (2024). Jaguar, Schr\u00f6dinger, LLC."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1021\/acs.jctc.7b00176","article-title":"Assessing DFT-D3 damping functions across widely used density functionals: Can we do better?","volume":"13","author":"Witte","year":"2017","journal-title":"J. Chem. Theory Comput."},{"key":"ref_55","unstructured":"Carb\u00f3, R., and Riera, J.M. (2012). A General SCF Theory, Springer Science & Business Media."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1063\/1.449880","article-title":"Direct inversion in the iterative subspace (DIIS) optimization of open-shell, excited-state, and small multiconfiguration SCF wave functions","volume":"84","author":"Hamilton","year":"1986","journal-title":"J. Chem. Phys."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/wcms.34","article-title":"Geometry optimization","volume":"1","author":"Schlegel","year":"2011","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: A webserver for the prediction of toxicity of chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"W422","DOI":"10.1093\/nar\/gkae236","article-title":"ADMETlab 3.0: An updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support","volume":"52","author":"Fu","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/17460441.2023.2267015","article-title":"The application of WaterMap-guided structure-based virtual screening in novel drug discovery","volume":"19","author":"Kaczor","year":"2024","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_61","unstructured":"Release, S. (2024). Desmond Molecular Dynamics System, DE Shaw Research, New York, NY, USA, 2024. Maestro-Desmond Interoperability Tools, Schr\u00f6dinger."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1021\/jp003020w","article-title":"Structure and dynamics of the TIP3P, SPC, and SPC\/E water models at 298 K","volume":"105","author":"Mark","year":"2001","journal-title":"J. Phys. Chem. A"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/00268977200100031","article-title":"NpT-ensemble Monte Carlo calculations for binary liquid mixtures","volume":"23","author":"McDonald","year":"1972","journal-title":"Mol. Phys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: Strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/662\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:24:52Z","timestamp":1760030692000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/5\/662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":64,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["ph18050662"],"URL":"https:\/\/doi.org\/10.3390\/ph18050662","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2025,4,30]]}}}